Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 21, 2023
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
Mason Carrico Reiterated (AKYA) at Buy and Held Target at $16 on, Mar 21st, 2023
Mason Carrico of Stephens & Co., Reiterated "Akoya Biosciences, Inc." (AKYA) at Buy and Held Target at $16 on, Mar 21st, 2023.
Mason has made no other calls on AKYA in the last 4 months.
There is 1 other peer that has a rating on AKYA. Out of the 1 peers that are also analyzing AKYA, 0 agree with Mason's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mason
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $17 on, Wednesday, March 8th, 2023
